Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study.

被引：9

作者：

Nizam, Amanda ^{[1
]}

Jindal, Tanya ^{[2
]}

Jiang, Cindy Y. ^{[3
]}

Alhalabi, Omar ^{[4
]}

Bakaloudi, Dimitra Rafailia ^{[5
]}

Talukder, Rafee ^{[6
]}

Davidsohn, Matthew P. ^{[7
]}

Nguyen, Charles B. ^{[8
]}

Oh, Eugene ^{[9
]}

Taylor, Amy K. ^{[10
]}

Lemke, Emily ^{[11
]}

Kilari, Deepak ^{[12
]}

Hoimes, Christopher J. ^{[13
]}

Emamekhoo, Hamid ^{[14
]}

Gupta, Shilpa ^{[15
]}

Bellmunt, Joaquim ^{[16
]}

Grivas, Petros ^{[17
,18
]}

Campbell, Matthew T. ^{[19
]}

Alva, Ajjai Shivaram ^{[20
]}

Koshkin, Vadim S. ^{[21
]}

机构：

[1] Cleveland Clin, Cleveland, OH USA

[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[3] Univ Texas MD Anderson Canc Ctr, Hematol Oncol Fellowship, Houston, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA

[5] Univ Washington, Dept Med, Div Oncol, Seattle, WA USA

[6] Baylor Coll Med, Houston, TX USA

[7] Albert Einstein Coll Med, New York, NY USA

[8] Univ Michigan, Rogel Comprehens Canc Ctr, Ann Arbor, MI USA

[9] Univ Michigan, Sch Med, Ann Arbor, MI USA

[10] Univ Wisconsin Hosp & Clin, Madison, WI USA

[11] Med Coll Wisconsin, Milwaukee, WI USA

[12] Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI USA

[13] Duke Univ, Duke Canc Inst, Durham, NC USA

[14] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[15] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[16] Dana Farber Canc Inst, Boston, MA USA

[17] Univ Washington, Div Hematol & Oncol, Seattle, WA USA

[18] Fred Hutchinson Canc Ctr, Seattle, WA USA

[19] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[20] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI USA

[21] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

283-183-138-12099; 613-135-2370-7650-2700; 6; 5; 3224; 1880; 62; 295; 3; 1; 38092-23700;

D O I：

10.1200/JCO.2024.42.4_suppl.537

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：537 / 537

页数：1

共 50 条

[41] Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden
Bellmunt, Joaquim
Powles, Thomas
Park, Se Hoon
Voog, Eric
Valderrama, Begona Perez
Gurney, Howard
Ullen, Anders
Loriot, Yohann
Sridhar, Srikala S.
Tsuchiya, Norihiko
Sternberg, Cora N.
Aragon-Ching, Jeanny B.
Petrylak, Daniel P.
Duran, Miguel A. Climent
Tyroller, Karin
Hoffman, Jason
Jacob, Natalia
Grivas, Petros
Gupta, Shilpa
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[42] Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC).
Talukder, Rafee
Bakaloudi, Dimitra Rafailia
Lin, Genevieve Ihsiu
Enright, Tom
Leary, Jacob Beck
Makrakis, Dimitrios
Tripathi, Nishita
Agarwal, Neeraj
Jindal, Tanya
Koshkin, Vadim S.
Brown, Jason R.
Johnson, Jeffrey
Zakharia, Yousef
Park, Joseph J.
Alva, Ajjai Shivaram
Barrera, Rafael Morales
Drakaki, Alexandra
Barata, Pedro C.
Khaki, Ali Raza
Grivas, Petros
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[43] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with histological subtypes
Loriot, Yohann
Gupta, Shilpa
Powles, Thomas
Grivas, Petros
Petrylak, Daniel P.
Tyroller, Karin
Jacob, Natalia
Hoffman, Jason
Bellmunt, Joaquim
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[44] Characterizing genomic alterations in patients with metastatic urothelial carcinoma (mUC) treated with enfortumab-vedotin (EV) with a focus on 1q23.3.
Saliby, Renee Maria
Semaan, Karl
Epstein, Ilana B.
Liria, Sonsoles
Dall, Christopher
Saad, Eddy
Eid, Marc
Canniff, John
Kwak, Lucia
Berg, Stephanie A.
Mantia, Charlene
McGregor, Bradley Alexander
Braun, David A.
Choueiri, Toni K.
Bellmunt, Joaquim
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[45] EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Petrylak, D. P.
Rosenberg, J. E.
Lee, J.
Yonese, J.
Duran, I.
Loriot, Y.
Sonpavde, G.
Wu, C.
Gartner, E. M.
Melhem-Bertrandt, A.
Powles, T.
ANNALS OF ONCOLOGY, 2019, 30
[46] Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study
Rikiya Taoka
Masaki Kamada
Kazuyoshi Izumi
Ryuta Tanimoto
Kei Daizumoto
Yushi Hayashida
Katsutoshi Uematsu
Hironobu Arai
Takeshi Sano
Ryoichi Saito
Hiromi Hirama
Toshihiro Kobayashi
Tomoko Honda
Yu Osaki
Yohei Abe
Hirohito Naito
Yoichiro Tohi
Yuki Matsuoka
Takuma Kato
Homare Okazoe
Nobufumi Ueda
Mikio Sugimoto
International Journal of Clinical Oncology, 2024, 29 : 602 - 611
[47] Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma
Rosenberg, J. E.
Powles, T.
Sonpavde, G. P.
Loriot, Y.
Duran, I.
Lee, J. L.
Matsubara, N.
Vulsteke, C.
Castellano, D.
Mamtani, R.
Sridhar, S. S.
Pappot, H.
Gurney, H. P.
Bedke, J.
Van der Heijden, M. S.
Campbell, M.
Wu, C.
Matsangou, M.
Petrylak, D. P.
ANNALS OF ONCOLOGY, 2021, 32 : S710 - S711
[48] Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study
Taoka, Rikiya
Kamada, Masaki
Izumi, Kazuyoshi
Tanimoto, Ryuta
Daizumoto, Kei
Hayashida, Yushi
Uematsu, Katsutoshi
Arai, Hironobu
Sano, Takeshi
Saito, Ryoichi
Hirama, Hiromi
Kobayashi, Toshihiro
Honda, Tomoko
Osaki, Yu
Abe, Yohei
Naito, Hirohito
Tohi, Yoichiro
Matsuoka, Yuki
Kato, Takuma
Okazoe, Homare
Ueda, Nobufumi
Sugimoto, Mikio
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (05) : 602 - 611
[49] EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
Rosenberg, J. E.
Powles, T.
Sonpavde, G. P.
Loriot, Y.
Duran, I.
Lee, J. -L.
Matsubara, N.
Vulsteke, C.
Castellano, D.
Mamtani, R.
Wu, C.
Matsangou, M.
Campbell, M.
Petrylak, D. P.
ANNALS OF ONCOLOGY, 2023, 34 (11) : 1047 - 1054
[50] Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy
Rosenberg, Jonathan E.
Mamtani, Ronac
Sonpavde, Guru P.
Loriot, Yohann
Duran, Ignacio
Lee, Jae-Lyun
Matsubara, Nobuaki
Vulsteke, Christof
Castellano, Daniel
Sridhar, Srikala S.
Pappot, Helle
Gurney, Howard
Bedke, Jens
van der Heijden, Michiel S.
Galli, Luca
Keam, Bhumsuk
Masumori, Naoya
Meran, Johannes
O'Donnell, Peter H.
Park, Se Hoon
Grande, Enrique
Sengelov, Lisa
Uemura, Hiroji
Skaltsa, Konstantina
Campbell, Mary
Matsangou, Maria
Wu, Chunzhang
Hepp, Zsolt
Mckay, Caroline
Powles, Thomas
Petrylak, Daniel P.
EUROPEAN UROLOGY, 2024, 85 (06) : 574 - 585

← 1 2 3 4 5 →